SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

CIK: 0001910264 · Show all filings

Period: Q4 2022 (← Previous) (Next →)

Filing Date: Feb 8, 2023

Total Value ($000): $273,945 (100.0% shares, 0.0% debt)

Holdings (5)

ACLX ARCELLX INC. 62.2%

Value ($000) $170,390 Shares 5,500,007 Est. Cost $16.72 Unrealized +37.2%

DSGN DESIGN THERAPEUTICS INC 24.4%

Value ($000) $66,962 Shares 6,526,476 Est. Cost $16.67 Unrealized -18.7%

SPRY ARS PHARMACEUTICALS 9.4%

Value ($000) $25,673 Shares 3,009,677 Est. Cost $6.49 Unrealized 0.0%

NKTX NKARTA INC. 2.9%

Value ($000) $7,987 Shares 1,333,333 Est. Cost $13.12 Unrealized -23.1%

— EFFECTOR THERAPEUTICS INC 1.1%

Value ($000) $2,934 Shares 6,822,114 Est. Cost $8.28 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	ARCELLX INC.	5,500,007	$170,390	62.2%	$16.72	+37.2%	COMMON STOCK	03940C100
DSGN	DESIGN THERAPEUTICS INC	6,526,476	$66,962	24.4%	$16.67	-18.7%	COM	25056L103
SPRY	ARS PHARMACEUTICALS	3,009,677	$25,673	9.4%	$6.49	0.0%	COM	82835W108
NKTX	NKARTA INC.	1,333,333	$7,987	2.9%	$13.12	-23.1%	COM	65487U108
—	EFFECTOR THERAPEUTICS INC	6,822,114	$2,934	1.1%	$8.28	—	COM	28202V108